Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2007
10/31/2007EP1848448A1 Use of a lyophilised bacterial lysate for the prevention of tuberculosis relapse
10/31/2007EP1848445A1 Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
10/31/2007EP1848444A1 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
10/31/2007EP1848443A2 Compounds useful for treating hiv
10/31/2007EP1848442A1 2-methylene-19-nor-(20s-24epi)-1alpha,25-dihydroxyvitamine-d2
10/31/2007EP1848441A1 Pharmaceutical composition comprising drospirenone and ethynylestradiol
10/31/2007EP1848440A1 Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
10/31/2007EP1848439A1 Oral immediate release formulation of a poorly watersoluble active substance
10/31/2007EP1848438A2 Diaminophenothiazine compositions and uses thereof
10/31/2007EP1848437A2 Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
10/31/2007EP1848436A2 Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association
10/31/2007EP1848435A2 Compounds for inflammation and immune-related uses
10/31/2007EP1848434A2 A method for treating heart failure
10/31/2007EP1848433A2 Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
10/31/2007EP1848432A1 Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
10/31/2007EP1848431A1 Liquid formulations for treatment of diseases or conditions
10/31/2007EP1848430A2 Novel benzylamine derivatives as cetp inhibitors
10/31/2007EP1848429A1 Pharmaceutical agents containing fluoroalkylated metal complexes and epothilone
10/31/2007EP1848428A2 Thiazole amides, imidazole amides and related analogues
10/31/2007EP1848427A1 Use of estrogen receptor-b selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis
10/31/2007EP1848426A2 Tricyclic cytoprotective compounds
10/31/2007EP1848425A1 Therapeutic combinations of manidi pine and a statin
10/31/2007EP1848424A2 Pharmaceutical composition comprising hydroxylated nebivolol
10/31/2007EP1848423A2 C10 cyclopropyl ester substituted taxane compositions
10/31/2007EP1848422A2 Method for decreasing cartilage damage in dogs
10/31/2007EP1848421A1 Natural remedy-dietary supplement combination product
10/31/2007EP1848420A2 Polymorphic forms of a gabaa agonist
10/31/2007EP1848419A2 Injectable preparations of diclofenic and its pharmaceutically acceptable salts
10/31/2007EP1848418A2 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
10/31/2007EP1848417A1 Formulations of ladostigil tartrate
10/31/2007EP1848416A2 Methods and materials with trans-clomiphene for the treatment of male infertility
10/31/2007EP1848415A1 Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
10/31/2007EP1848414A2 Method for treating gefitinib resistant cancer
10/31/2007EP1848413A1 Parenteral combination therapy for infective conditions with drug resistant bacterium
10/31/2007EP1848412A2 Transdermal systems having control delivery system
10/31/2007EP1848409A1 Propranolol formulations
10/31/2007EP1848408A1 Propranolol formulations
10/31/2007EP1848407A2 Oral pharmaceutical composition
10/31/2007EP1848402A1 Rasagiline formulations of improved content uniformity
10/31/2007EP1848400A1 Analgesic compositions
10/31/2007EP1848290A2 Compositions and methods for nutrition supplementation
10/31/2007EP1848278A2 Oral formulations for delivery of catecholic butanes including ndga compounds
10/31/2007EP1848275A1 Kappa opioid receptor ligands
10/31/2007EP1848273A1 18-membered macrocycles and analogs thereof
10/31/2007EP1848270A2 Transmucosal administration of drug compositions for treating and preventing disorders in animals
10/31/2007EP1771180B1 Composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol, an alcohol phase and an oily phase
10/31/2007EP1766044A4 Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
10/31/2007EP1755606B1 Quinazolinone derivatives useful as vanilloid antagonists
10/31/2007EP1755584A4 Treatment of myopia
10/31/2007EP1755409B1 Topical application of marine oils to foods
10/31/2007EP1727539B1 Use of rotigotine for treating and preventing parkinson's plus syndrome
10/31/2007EP1644380B1 Biologically active neopeltolide compounds
10/31/2007EP1636206B1 Imidazole derivatives as glutmate receptor antagonists
10/31/2007EP1620093A4 Pesticidal (dihalopropenyl) phenylalkyl substituted benzoxazole and benzothiazole derivatives
10/31/2007EP1587505A4 Wound and skin care compositions
10/31/2007EP1581252A4 Wound and skin care products
10/31/2007EP1539795B1 Crystalline 17beta-hydroxy-7alpha-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma-lactone
10/31/2007EP1537122B9 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
10/31/2007EP1534678B1 Pleuromutilin derivatives as antimicrobbials
10/31/2007EP1531807A4 Bazedoxifene treatment regimens
10/31/2007EP1524985B8 Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated cpg motifs
10/31/2007EP1513821B1 Protein kinase inhibitors
10/31/2007EP1512402B1 Inhibitors against complex ii of electron transport system
10/31/2007EP1509606B1 Allergen from mugwort pollen
10/31/2007EP1503760A4 Camptothecin derivatives and polymeric conjugates thereof
10/31/2007EP1496896A4 Inhibitors of akt activity
10/31/2007EP1470143B1 Compounds that inhibit factor xa activity
10/31/2007EP1448551B1 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
10/31/2007EP1448198B1 Nicotin-or isonicotin benzothiazole derivatives
10/31/2007EP1420801B1 Use of fucans in the treatment of adhesions, arthritis and psoriasis
10/31/2007EP1404331B1 Sustained release formulations of oxymorphone
10/31/2007EP1392665B1 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
10/31/2007EP1368301B1 Side-chain halogenated amino carboxylic acid derivatives as medicaments for treating cardiovascular diseases
10/31/2007EP1362854B1 Benzo[b[thiophene derivatives and process for producing the same
10/31/2007EP1318980B1 Hydroxamate derivatives useful as deacetylase inhibitors
10/31/2007EP1289993B1 Caspase inhibitors and uses thereof
10/31/2007EP1286998B2 Oxazolidinone derivatives with antibiotic activity
10/31/2007EP1246795B1 Antibacterial agents
10/31/2007EP1242426B1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
10/31/2007EP1218337B1 Synthesis of 3,5,7|-1h-imidazo 1,5-a|imidazol-2(3h)-one compounds
10/31/2007EP1192247B9 Sphingosine kinase enzyme
10/31/2007EP1153013B1 5-ht1f agonists
10/31/2007EP1144384B1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/31/2007EP1140198B1 Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
10/31/2007EP1078079B1 Methods of forming protein-linked lipidic microparticles, and compositions thereof
10/31/2007EP0998576B1 Method for producing a recombinant bovine adenovirus vector
10/31/2007EP0910564B1 D-amino acid derived inhibitors of cysteine and serine proteases
10/31/2007DE60125750T2 Pharmazeutische formulierung enthaltend trägerkügelchen mit aufgebrachter schicht aus valaciclovir A pharmaceutical formulation comprising carrier beads made with an applied layer valaciclovir
10/31/2007DE102006020035A1 Herstellung und Verwendung von Poly(hydroxyethylstärke)chitin- und Poly(Carboxymethylstärke)chitin-Verbindungen Preparation and use of poly (hydroxyethyl) chitin and poly (carboxymethyl) chitin-compounds
10/31/2007DE102006019907A1 Use of substituted glycerin derivative in the preparation of a pharmaceutical composition for the prevention or treatment of e.g. cancer disease, pathological sequence of alcohol abuse, viral hepatitis and toxic nerve disorder
10/31/2007DE102006019906A1 Verwendung von Verbindungen der Formel ARX oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung Use of compounds of the formula ARX, or their pharmaceutically acceptable salts for the manufacture of a pharmaceutical preparation
10/31/2007DE102006019619A1 Kristalline Modifikation von Cefuroximaxetil Crystalline modification of cefuroxime axetil
10/31/2007DE102006019597A1 Spirocyclische Cyclohexan-Derivate Spirocyclic cyclohexane derivatives
10/31/2007DE102006018972A1 Agent, useful for topical treatment of skin disease e.g. psoriasis, neurodermatitis and eczema, comprises coal tar solution, a component of talc, bismuth gallate or sulfur fine-particles, surfactant and optionally carriers or diluents
10/31/2007DE102006011574A1 Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln Substituted imidazo [2,1-b] thiazole compounds and their use for the preparation of medicaments
10/31/2007DE102005055355A1 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate 3,6-dihydro-2-oxo-6H- [1,3,4] thiadiazine derivatives
10/31/2007DE102005055354A1 Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine Substituted 5-phenyl-3,6-dihydro-2-oxo-6H- [1,3,4] thiadiazine
10/31/2007DE10134478B4 Verfahren zur Darstellung von thiazolsubstituierten β-Lactamen A process for the preparation of β-lactams thiazolsubstituierten
10/31/2007DE10014639B4 cDNSen mit einer Kodierung von Enzymen zur Fructan-Synthese mit einer Niedertemperatur-Expression sowie Verfahren zu deren Isolierung cDNSen with a coding for enzymes of fructan synthesis with a low-temperature expression as well as methods for their isolation
10/31/2007CN200966670Y Intra-uterine contraceptive device
1 ... 3523 3524 3525 3526 3527 3528 3529 3530 3531 3532 3533 3534 3535 3536 3537 3538 3539 3540 3541 3542 3543 ... 7860